Losartan and Memory

PTSD Clinical Trial

Official title:

The Effect of Losartan on Emotion Regulation

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05828940
• Other study ID #: R58494/RE003
• Status: Completed
• Phase: N/A
• Start date: October 1, 2019
• Est. completion date: March 31, 2022

Study information

• Verified date: April 2023
• Source: University of Oxford
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study investigates the effect of a single dose of 50mg losartan vs placebo on BOLD signal during memory encoding.

Description:

The commonly prescribed antihypertensive drug losartan targets the renin-angiotensin system - a hormone system regulating blood pressure - by acting as an angiotensin receptor antagonist. The drug prevents a docking of the protein angiotensin IV to AT1 receptors, which leads to a dilation if vessels and a reduction in blood pressure. However, the increase in free angiotensin IV has also been associated with an increase in synaptic plasticity, the cellular mechanism involved in learning and memory. As such, losartan appears to have cognition-enhancing properties, in a way that a single dose of 50mg improves prospective memory in healthy humans . However, preliminary pre-clinical results also suggest that a single injection of the drug improves fear extinction in rodents, which is the equivalent to human cognitive-behavioural therapy for anxiety disorders . Furthermore, compared to other antihypertensive drugs, regular losartan treatment appears to prevent the development of post-traumatic stress disorder following trauma exposition . Such results suggest that the renin-angiotensin system may play a key role in the prevention of anxiety.

In this study, we investigate the effect kof probing the renin-angiotensin system on memory encoding, which has previously been shown to be impaired in PTSD. In a double-blind, randomised between-groups design, 40 healthy volunteers with moderate to high levels of trait anxiety are randomised to a group receiving a single dose of losartan (50mg) versus placebo. When peak plasma levels are reached, participants work on a battery of behavioural and neural measures of emotional information processing. These tasks will include an fMRI task where participants will see images of animals and landscapes on the screen and categorise these accordingly, to be tested for memory for these images in a later task.

The results from this study will help us understand how the renin-angiotensin system affects memory formation, and they will help us establish a battery of tasks that sensitively respond to such manipulations. Such information will ultimately lead to the development of losartan and similar agents for the more effective and more compact treatment of anxiety disorders.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 41
• Est. completion date: March 31, 2022
• Est. primary completion date: March 31, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 50 Years

Eligibility

Inclusion Criteria:

• willing and able to provide informed consent

• male or Female, aged 18-50 years

• body mass index (BMI) of 18-30 kg/m2

• non- or light-smoker (< 5 cigarettes a day)

• STAIT score of at least 40

Exclusion Criteria:

• Female participant who is pregnant or breast-feeding

• CNS-active medication during the last 6 weeks

• Current blood pressure or other heart medication (especially aliskiren or beta blockers)

• Diagnosis of intravascular fluid depletion or dehydration

• Past or present DSM-IV axis-I diagnosis or suspected diagnosis (from SCID results at screening)

• Alcohol or substance abuse

• First-degree family member with a history of a severe psychiatric disease

• Impaired liver or kidney function

• Lifetime history of epilepsy or other neurological disease, systemic infection, or clinically significant hepatic, cardiac, obstructive respiratory, renal, cerebrovascular, metabolic, endocrine or pulmonary disease or disorder which, in the opinion of the investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study.

• High or moderate risk of coronavirus, based on the NHS checklist for coronavirus vulnerability https://www.nhs.uk/conditions/coronavirus-covid-19/people-at-higher-risk/whos-at-highe r-risk-from-coronavirus/

• Contraindication to MRI (e.g. metal implant)

• Insufficient English skills

• participated in another study involving CNS-active medication during the last 6 weeks Participants will also not be able to take part if they are left-handed, due to the research MRI aspect of the study relying on group means.

Related Conditions & MeSH terms

• PTSD

Intervention

Drug:
• Losartan Potassium
oral tablet, over-encapsulated
• Placebo
oral tablet, over-encapuslated

Locations

Country	Name	City	State
United Kingdom	Department of Psychiatry, University of Oxford	Oxford

Sponsors (1)

Lead Sponsor	Collaborator
University of Oxford

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	BOLD activation in hippocampus during new>familiar contrast		one hour after capsule intake
Secondary	BOLD activation in other brain areas		one hour after capsule intake
Secondary	pattern similarity		one hour after capsule intake